Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ...

An announcement from Akeso, Inc. ( (HK:9926) ) is now available. Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Concentra Group Holdings Parent, Inc.'s acquisitions and solid financials position it for growth in the U.S. occupational ...

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report ...

MSD partners LaNova Medicines on a PD-1 and VEGF targeting candidate for cancer, a potential replacement for its top-seller Keytruda.

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

In a case of consolidation in the Chinese pharma sector, LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million. Under the terms of the ...

In addition, Akeso has recently had positive read-outs in three single-region (China), randomized Phase III clinical trials for ivonescimab in NSCLC: HARMONi-A, HARMONi-2, and HARMONi-6.